Amplia Therapeutics (ASX:ATX) YoY EPS Growth: 36.36% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATX Amplia Therapeutics Ltd ASX:ATX
27 GF Score
Price A$0.13
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics YoY EPS Growth?

Amplia Therapeutics ASX:ATX -3.70% 27 YoY EPS Growth is 36.36% as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 27/100. The stock has 2 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Amplia Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2026 was 36.36%.

Amplia Therapeutics's Earnings per Share (Diluted) for the six months ended in Mar. 2026 was A$-0.01.

Amplia Therapeutics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics YoY EPS Growth Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.35 -29.17 29.03 4.55 23.81

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.25 -83.33 35.29 9.09 36.36
ASX:ATX
27GF Score
Amplia Therapeutics Ltd ASX:ATX
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Amplia Therapeutics's YoY EPS Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EPS Growth (A: Mar. 2026 )
=(Earnings per Share (Diluted) (A: Mar. 2026 )-Earnings per Share (Diluted) (A: Mar. 2025 ))/ | Earnings per Share (Diluted) (A: Mar. 2025 ) |
=(-0.016--0.021)/ | -0.021 |
=23.81 %

Amplia Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EPS Growth (Q: Mar. 2026 )
=(Earnings per Share (Diluted) (Q: Mar. 2026 )-Earnings per Share (Diluted) (Q: Mar. 2025 )) / | Earnings per Share (Diluted) (Q: Mar. 2025 )) |
=(-0.007--0.011)/ | -0.011 |
=36.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 36.36% mean?
Amplia Therapeutics (ASX:ATX) has a YoY EPS Growth of 36.36% as of Mar. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Amplia Therapeutics and its competitors.
Is Amplia Therapeutics' YoY EPS Growth too high?
Amplia Therapeutics' current YoY EPS Growth is 36.36%. Overall, Amplia Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' YoY EPS Growth compare to VRTX and REGN?
Amplia Therapeutics' YoY EPS Growth of 36.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Amplia Therapeutics and its competitors. Amplia Therapeutics's current YoY EPS Growth is 36.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current YoY EPS Growth of 36.36%. The current YoY EPS Growth is 36.36%. Amplia Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current YoY EPS Growth is 36.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
27GF Score

Get the complete analysis for ASX:ATX

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price